|
Back to Home » June 2021 News » Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function |
Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function |
June 28, 2021
LEXINGTON, Mass., June 28, 2021 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced top-line results of the U.S.-based iLeukPulm clinical trial of inhaled Leukine (sargramostim, yeast-derived recombinant human granulocyte macrophage colony stimulating factor (GM-CSF)) in...
Source URL: https://www.prnewswire.com:443/news-releases/second-randomized-trial-of-leukine-sargramostim-in-covid-19-demonstrates-improvement-in-lung-function-301320732.html
|
|
|
|
